Autoimmune Diseases  >>  Artlegia (olokizumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Artlegia (olokizumab) / R-Pharm
NCT01242488 / 2010-020839-39: Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

Checkmark EULAR 2016
May 2016 - May 2016: EULAR 2016
Checkmark Rheumatoid arthritis
Mar 2014 - Mar 2014: Rheumatoid arthritis
Checkmark P2 data (RA)
More
Completed
2
221
US, Europe
CDP6038, Tocilizumab (Actemra or RoActemra), Placebo sc, Placebo iv
UCB Pharma
Rheumatoid Arthritis
06/12
06/12
NCT01463059: Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Completed
2
119
Japan, RoW
Placebo, Olokizumab 60 mg, CDP6038, Olokizumab 120 mg, Olokizumab 240 mg
UCB Japan Co. Ltd.
Rheumatoid Arthritis
02/13
02/13

Download Options